Review update - May 2011
Technology Appraisal no 181; Pemetrexed for the first-line treatment of non-small-cell lung cancer
Whilst considering a proposal for a review of TA181, NICE became aware of an independent Health Technology Assessment (HTA) report on First-line therapy for adult patients with non-small-cell lung cancer currently being compiled by the Liverpool Review and Implementation Group (LRiG), Liverpool University. This HTA is anticipated to publish in mid 2011.
The results of the HTA report may have a significant impact upon the consideration to review TA181. Consequently Guidance Executive has decided that the consideration to review the original guidance will be deferred until mid 2011 to coincide with publication of the Health Technology Assessment. At this point the evidence base will again be assessed to ascertain the need for a review of the guidance.
This page was last updated: 23 May 2011